Comparative Pharmacology
Head-to-head clinical analysis: VISKAZIDE versus ZEBETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VISKAZIDE versus ZEBETA.
VISKAZIDE vs ZEBETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker). Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
Initial dose 5 mg orally twice daily; may increase to 10 mg twice daily after 2 weeks; maximum 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Terminal elimination half-life is 12–15 hours in patients with normal renal function, allowing once-daily dosing.
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Approximately 50% of an oral dose is excreted unchanged in urine; the remainder is hepatically metabolized with biliary excretion of metabolites contributing to fecal elimination.
Category C
Category C
Beta Blocker/Thiazide Diuretic Combination
Beta Blocker